The Roles of Alternative Splicing in Tumor-immune Cell Interactions

Author:

Wang Yue1,Zhang Honglei2,Jiao Baowei2,Nie Jianyun1,Li Xiyin1,Wang Wenhuan1,Wang Hairui1

Affiliation:

1. Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China

2. State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China

Abstract

Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and protumoral roles in different types of cancer. For example, ULBP1_RI, MLL5Δ21spe, NKp44-1Δ5, MHC-IΔ7, CD200SΔ1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and IPAK4-L and, FOXP1ΔN100 exhibit functions in hematological cancers.

Funder

National Natural Science Foundation of China

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference113 articles.

1. Tran E.; Robbins P.F.; Rosenberg S.A.; Final common pathway’ of human cancer immunotherapy: Targeting random somatic mutations. Nat Immunol 2017,18(3),255-262

2. Paucek R.D.; Baltimore D.; Li G.; The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends Immunol 2019,40(4),292-309

3. Rapoport A.P.; Stadtmauer E.A.; Binder-Scholl G.K.; Goloubeva O.; Vogl D.T.; Lacey S.F.; Badros A.Z.; Garfall A.; Weiss B.; Finklestein J.; Kulikovskaya I.; Sinha S.K.; Kronsberg S.; Gupta M.; Bond S.; Melchiori L.; Brewer J.E.; Bennett A.D.; Gerry A.B.; Pumphrey N.J.; Williams D.; Tayton-Martin H.K.; Ribeiro L.; Holdich T.; Yanovich S.; Hardy N.; Yared J.; Kerr N.; Philip S.; Westphal S.; Siegel D.L.; Levine B.L.; Jakobsen B.K.; Kalos M.; June C.H.; NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015,21(8),914-921

4. Robbins P.F.; Morgan R.A.; Feldman S.A.; Yang J.C.; Sherry R.M.; Dudley M.E.; Wunderlich J.R.; Nahvi A.V.; Helman L.J.; Mackall C.L.; Kammula U.S.; Hughes M.S.; Restifo N.P.; Raffeld M.; Lee C.C.; Levy C.L.; Li Y.F.; El-Gamil M.; Schwarz S.L.; Laurencot C.; Rosenberg S.A.; Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011,29(7),917-924

5. Ott P.A.; Hu Z.; Keskin D.B.; Shukla S.A.; Sun J.; Bozym D.J.; Zhang W.; Luoma A.; Giobbie-Hurder A.; Peter L.; Chen C.; Olive O.; Carter T.A.; Li S.; Lieb D.J.; Eisenhaure T.; Gjini E.; Stevens J.; Lane W.J.; Javeri I.; Nellaiappan K.; Salazar A.M.; Daley H.; Seaman M.; Buchbinder E.I.; Yoon C.H.; Harden M.; Lennon N.; Gabriel S.; Rodig S.J.; Barouch D.H.; Aster J.C.; Getz G.; Wucherpfennig K.; Neuberg D.; Ritz J.; Lander E.S.; Fritsch E.F.; Hacohen N.; Wu C.J.; An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017,547(7662),217-221

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3